Related Experiment Video
Updated: Jun 8, 2026
Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
Published on: September 16, 2018
Reappraisal of MMR vaccines currently used in Korea
Hyunju Lee1, Han Wool Kim, Hye Kyung Cho
1Department of Pediatrics, Ewha Womans University School of Medicine, Seoul, Korea.
Insights
The measles, mumps, and rubella (MMR) vaccines demonstrate strong immunogenicity and a favorable safety profile in Korean children. These findings support the use of current MMR vaccines and inform future vaccination strategies.
Area of Science:
- Pediatrics
- Immunology
- Vaccinology
Background:
- Limited studies exist on currently utilized MMR vaccines in Korea.
- This study addresses the need for evaluating the immunogenicity and safety of MMR vaccines in the Korean pediatric population.
Purpose of the Study:
- To assess the immunogenicity and safety of two MMR vaccines in Korean children.
- To provide data supporting current vaccination practices and future vaccine introductions.
Main Methods:
- Two age groups were enrolled: 12-23 months and 4-6 years, receiving either Priorix™ or MMRII®.
- Antibody levels were measured using ELISA pre- and post-vaccination.
- Safety monitoring included local adverse events (5 days) and systemic adverse events (42 days).
Main Results:
- High seroconversion rates were observed for all three components (measles, mumps, rubella) in both age groups.
- Reported adverse events were generally mild and comparable between the two vaccines.
- No serious vaccine-related adverse events were reported, indicating a good safety profile.
Conclusions:
- MMR vaccines elicit robust immunogenic responses in Korean children.
- The evaluated MMR vaccines are safe for use in pediatric populations.
- These findings contribute valuable data for the introduction of diverse vaccines in the future.
Background:
Although MMR vaccine is widely used in Korea, there are limited studies on the currently used vaccines. We evaluated the immunogenicity and safety of MMR vaccines in Korean children.
Methods:
For first and second dose immunization, children aged 12-23 months and 4-6 years were enrolled. All subjects received a single dose of either Priorix™ (Glaxo Smithkline Biologicals, Rixensart, Belgium) or MMRII® (Merck & Co., Inc., West Point, PA, USA). Pre- and postvaccine sera were collected from all participants. Antibody levels were determined by ELISA (Enzygnost®; Dade Behring, Schwalbach, Germany). Safety monitoring included local adverse events for 5 days and systemic adverse events for 42 days following vaccination.
Results:
One hundred twenty-one subjects were enrolled in the 12-23 months age group and 39 in the 4-6 years age group. The seroconversion rate in the 12-23 months age group was 97.9-100.0% for measles, 85.1-88.9% for mumps and 100.0% for rubella. All children 4-6 years of age previously seronegative showed seroconversion for measles, mumps and rubella. Local adverse events were reported in 8.3-16.1% (12-23 months age) and 27.8-31.6% (4-6 years age), and 40.0-48.2% (12-23 months age) and 42.1-61.1% (4-6 years age) experienced at least more than 1 systemic adverse reaction. No vaccine-related serious adverse events were reported. Among the same age groups, there was no significant difference in adverse events between the two vaccines.
Conclusion:
The MMR vaccines are safe and show good immunogenic responses in children. These data will be invaluable when we introduce diverse vaccines in the following future.
More Related Videos
Related Concept Videos
01:29Microorganisms in Medicine and Therapeutics
01:51Vaccinations
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...